Loading…

Discharge treatment with angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction

Background Medical therapy could improve the prognosis of real‐life patients discharged after a heart failure (HF) hospitalisation. Aim To determine the impact of discharge HF treatment on mortality and readmissions in different left ventricular ejection fraction (LVEF) groups. Methods Multicentre p...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2019-12, Vol.49 (12), p.1505-1513
Main Authors: Vicent, Lourdes, Cinca, Juan, Vazquez‐García, Rafael, Gonzalez‐Juanatey, José R., Rivera, Miguel, Segovia, Javier, Pascual‐Figal, Domingo, Bover, Ramón, Worner, Fernando, Delgado‐Jiménez, Juan, Fernández‐Avilés, Francisco, Martínez‐Sellés, Manuel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Medical therapy could improve the prognosis of real‐life patients discharged after a heart failure (HF) hospitalisation. Aim To determine the impact of discharge HF treatment on mortality and readmissions in different left ventricular ejection fraction (LVEF) groups. Methods Multicentre prospective registry in 20 Spanish hospitals. Patients were enrolled after a HF hospitalisation. Results A total of 1831 patients was included (583 (31.8%) HF with reduced ejection fraction (HFrEF); 227 (12.4%) HF with midrange ejection fraction (HFmrEF); 610 (33.3%) HF with preserved ejection fraction (HFpEF), and 411 (22.4%) with unknown LVEF). Angiotensin‐converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB) at discharge were independently associated with a reduction in: (i) all‐cause mortality: hazard ratio (HR) 0.55, 95% confidence interval (CI) 0.41–0.74, P < 0.001, with a similar effect in the four groups; (ii) mortality due to refractory HF HR 0.45, 95% CI 0.29–0.64, P < 0.001, with a similar effect in the three groups with known LVEF; (iii) mortality/HF admissions (HR 0.61; 95% CI: 0.50–0.74), more evident in HFrEF (HR 0.54; 95% CI: 0.38–0.78) compared with HRmEF (HR 0.64; 95% CI 0.40–1.02), or HFpEF (HR 0.70; 95% CI 0.53–0.92). In patients with HFrEF triple therapy (ACE inhibitor/ARB + beta blocker + mineralocorticoid receptor antagonist) was associated with the lowest mortality risk (HR 0.21; 95% CI: 0.08–0.57, P = 0.002) compared with patients that received none of these drugs. Conclusions Discharge treatment with ACE inhibitor/ARB after a HF hospitalisation is associated with a reduction in all‐cause and refractory HF mortality, irrespective of LVEF.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.14289